(HSGX:Consolidated Issue listed on NASDAQ Global Market)
Peter S. Greenleaf
Former Chief Executive Officer and Director, Histogenics Corporation
|Age||Total Calculated Compensation||This person is connected to 107 board members in 2 different organizations across 7 different industries.|
See Board Relationships
As of Fiscal Year 2013
Mr. Peter S. Greenleaf has been the Chief Executive Officer of Sucampo Pharmaceuticals, Inc. since March 03, 2014. Mr. Greenleaf served as Chief Executive Officer of Histogenics Corporation from June 10, 2013 to February 28, 2014 and served as its President. Mr. Greenleaf served as President of MedImmune, LLC (also known as MedImmune, Inc.). Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group, ...
830 Winter StreetPhone: 781-547-7900
Waltham, Massachusetts 02451
Board Members Memberships*
Former Chief Executive Officer and Director
Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee
Saint Joseph's University
Western Connecticut State University
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Mark R. Baker J.D.||Chief Executive Officer, Director and Member of Science & Strategy Committee|
Progenics Pharmaceuticals, Inc.
|Craig A. Wheeler||Chief Executive Officer, President and Executive Director|
Momenta Pharmaceuticals Inc.
|A. J. Kazimi MBA||Founder, Chairman, Chief Executive Officer and President|
Cumberland Pharmaceuticals, Inc.
|Douglas L. Drysdale||Chairman, Chief Executive Officer and President|
Pernix Therapeutics Holdings, Inc.
|Jeffrey M. Yordon||Founder, Chairman and Chief Executive Officer|
Sagent Pharmaceuticals, Inc.
|$615.2K||Compensation as of Fiscal Year 2013.|